Axogen Inc. (AXGN) 3.45 $AXGN
AxoGen, Inc. Announces Closing of Public Offering of Common Stock
GlobeNewswire - Tue Feb 10, 3:35PM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company with a unique and innovative portfolio of products used to repair injured peripheral nerves, today announced the closing of its previously announced underwritten public offering of 4,728,000 shares of its common stock at a price to the public of $2.75 per share resulting in gross proceeds to AxoGen from the offering of approximately $13.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by AxoGen. In addition, the Company announced that the underwriter fully exercised its over-allotment option for the purchase of an additional 709,200 shares, which will result in additional gross proceeds of approximately $2.0 million. The closing of the over-allotment option is expected to be completed on or about February 13, 2015, subject to customary closing conditions. Wedbush PacGrow Life Sciences has acted as sole manager for the offering.
AXGN: 3.45 (+0.02)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 11:45AM CST
IMMU: 3.84 (unch), AXGN: 3.45 (+0.02), CLW: 63.20 (-0.74), QKLS: 2.10 (-0.24), EOPN: 8.55 (-0.01), HSNI: 67.32 (+1.52), LQDT: 9.52 (+0.09), EOX: 1.15 (unch), GLUU: 5.12 (+0.14), WSTL: 1.45 (+0.10), LFVN: 1.11 (-0.02), HSP: 87.35 (unch), GENE: 8.04 (+1.90), ADEP: 6.93 (-0.30), EARS: 5.88 (-0.01), IVC: 17.13 (+0.15), QUIK: 2.17 (+0.01), ENRJ: 2.81 (+0.06), FARM: 24.00 (-0.19), OSUR: 8.13 (+0.06)
AxoGen, Inc. Prices Public Offering of Common Stock
GlobeNewswire - Thu Feb 05, 10:00AM CST
via PRWEB - AxoGen, Inc. (Nasdaq:AXGN), a leading medical technology company with a unique and innovative portfolio of products used to repair injured peripheral nerves, has announced the pricing of an underwritten public offering of 4,728,000 shares of its common stock, offered at a price to the public of $2.75 per share. The gross proceeds to AxoGen from this offering are expected to be approximately $13.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by AxoGen. AxoGen has granted the underwriter an option to purchase up to an additional 709,200 shares during the next 30 days. The offering is expected to close on or about February 10, 2015, subject to customary closing conditions. Wedbush PacGrow Life Sciences is acting as sole manager for the offering.
AXGN: 3.45 (+0.02)
AxoGen, Inc. Announces Proposed Public Offering of Common Stock
GlobeNewswire - Wed Feb 04, 3:29PM CST
via PRWEB - AxoGen, Inc. (Nasdaq:AXGN), a leading medical technology company with a unique and innovative portfolio of products used to repair injured peripheral nerves, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Wedbush PacGrow Life Sciences is acting as sole manager for the offering.
AXGN: 3.45 (+0.02)
AxoGen, Inc. Announces Preliminary Fourth Quarter and Full Year Revenue
GlobeNewswire - Wed Feb 04, 3:17PM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company with a unique and innovative portfolio of products used to repair injured peripheral nerves, today announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2014.
AXGN: 3.45 (+0.02)
AxoGen, Inc. to Host Surgeon Education Event at AAHS ASPN ASRM Joint 2015 Annual Meeting
GlobeNewswire - Thu Jan 22, 6:09AM CST
via PRWEB - AxoGen, Inc. (Nasdaq:AXGN), a leading medical technology company focused on the peripheral nerve repair market, announced that it will sponsor an educational forum for surgeons at the Joint Annual Meetings of the American Association for Hand Surgery, American Society for Peripheral Nerve and American Society for Reconstructive Microsurgery, taking place January 21-27 in Paradise Island, Bahamas.
AXGN: 3.45 (+0.02)
AxoGen, Inc. CMO Jill Schiaparelli and Oral Maxillofacial Surgeon Dr. Shahrokh Bagheri to Discuss Nerve Injury and Repair Options Live on iHeart Business Talk Radio HealthTech Talk Live -- January 10, 2015
Marketwired - Fri Jan 09, 6:15AM CST
AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company dedicated to peripheral nerve repair, announced today that Chief Marketing Officer Jill Schiaparelli will be interviewed live on iHeart Radio's debut episode of HealthTech Talk Live hosted by Ben Chodor and broadcast nationwide on iHeart Radio/ Clear Channel Atlanta Studios - 640 WGST AM this Saturday at 3:00 pm ET. In this exclusive double-segment interview, Ms. Schiaparelli will discuss AxoGen's portfolio of peripheral nerve repair solutions that offers alternatives to patients who require surgical repair of injured peripheral nerves. She will be joined by oral and maxillofacial surgeon and trigeminal nerve repair expert Dr. Shahrokh Bagheri, Chair of Oral and Maxillofacial Surgery at Northside Hospital in Atlanta, to talk about the impact of oral nerve injuries on patients.
AXGN: 3.45 (+0.02)
AxoGen, Inc. CMO Jill Schiaparelli and Oral Maxillofacial Surgeon Dr. Shahrokh Bagheri to Discuss Nerve Injury & Repair Options Live on iHeart Radio HealthTech Talk Live
GlobeNewswire - Fri Jan 09, 6:03AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company dedicated to peripheral nerve repair, announced today that Chief Marketing Officer Jill Schiaparelli will be interviewed live on iHeart Radio's debut episode of HealthTech Talk Live, hosted by Ben Chodor, and broadcasted nationwide on iHeart Radio / Clear Channel Atlanta Studios - 640 WGST AM, this Saturday at 3:00 pm ET. In this exclusive double-segment interview, Ms. Schiaparelli will discuss AxoGen's portfolio of peripheral nerve repair solutions that offers alternatives to patients who require surgical repair of injured peripheral nerves. She will be joined by oral and maxillofacial surgeon and trigeminal nerve repair expert Dr. Shahrokh Bagheri, Chair of Oral and Maxillofacial Surgery at Northside Hospital in Atlanta, about the impact of oral nerve injuries on patients.
AXGN: 3.45 (+0.02)
AxoGen, Inc. Promotes Jill Schiaparelli to Chief Marketing Officer
GlobeNewswire - Tue Jan 06, 6:02AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a growing medical technology company with a unique and innovative portfolio of products used to repair injured peripheral nerves, announced that Jill Schiaparelli has been promoted to the role of Chief Marketing Officer and will focus on the strategy to develop current and expansion nerve repair markets as well as brand and corporate marketing.
AXGN: 3.45 (+0.02)
Will AxoGen (AXGN) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 7:13AM CST
Will AxoGen (AXGN) Continue to Surge Higher?
AXGN: 3.45 (+0.02)
Zacks Rank #1 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
BRLI: 34.63 (+0.06), AXGN: 3.45 (+0.02), AZPN: 38.40 (+0.79), ARQL: 1.35 (+0.04), ADUS: 21.57 (+0.18)
AxoGen, Inc. Avance(R) Nerve Graft Recipient to be honored on Donate Life Rose Parade Float on New Year's Day
GlobeNewswire - Tue Dec 23, 6:02AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a high-growth medical technology company with a unique and innovative portfolio of products used to repair injured peripheral nerves, announced that Shirley Pincus, one of the thousands of patients who have had injured nerves repaired with AxoGen's Avance(R) Nerve Graft, will be honored as a recipient of donated nerve tissue as a float rider in the 2015 Rose Parade aboard the Donate Life Rose Parade Float in Pasadena, California on New Year's Day.
AXGN: 3.45 (+0.02)
AxoGen, Inc. (AXGN) Jumps 5.45% on Insider Buying - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 8:18AM CST
AxoGen, Inc. (AXGN) was a big mover last session, as the company saw its shares rise by over 5% on the day.
AXGN: 3.45 (+0.02), AKRX: 47.28 (-0.25)
PDS Biotechnology, Inc. Announces Appointment of Biotech Industry Leader Sir Richard Sykes to its Board of Directors as Executive Chairman
PR Newswire Europe - Thu Dec 18, 9:41AM CST
PDS Biotechnology, a clinical stage immunotherapeutics company developing the powerful Versamune(R) nanoparticle technology, is delighted to announce that Sir Richard Sykes has accepted an invitation to join the company's board of directors as Executive Chairman.
AXGN: 3.45 (+0.02)
AxoGen perks up
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 8:22AM CST
AXGN: 3.45 (+0.02)
Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
BGFV: 12.53 (+0.17), AXGN: 3.45 (+0.02), BRK.B: 148.34 (-1.45), Y: 475.43 (-0.18), BIOD: 1.38 (-0.14)
AxoGen, Inc. CEO Karen Zaderej to Be Interviewed on Clear Channel - iHeart Business Talk Radio's "The Trader's Network" on December 2
GlobeNewswire - Tue Dec 02, 6:17AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a high-growth medical technology company focused on the peripheral nerve repair market, announced today that Chief Executive Officer (CEO) Karen Zaderej will be interviewed live by host Michael Yorba on Clear Channel - iHeart Business Talk Radio's "The Trader's Network" Show. In this exclusive interview, Ms. Zaderej will discuss AxoGen's unique and innovative portfolio of peripheral nerve repair solutions that offer alternatives to the more than 900,000 patients each year who require surgical repair of an injured peripheral nerve. She will also discuss the Company's strong year-on-year growth and its strategy for becoming the market leader of the $1.6 billion peripheral nerve repair market in the US.
AXGN: 3.45 (+0.02)
AxoGen, Inc. Announces Closing of Public Offering of Common Stock
GlobeNewswire - Tue Feb 10, 3:35PM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company with a unique and innovative portfolio of products used to repair injured peripheral nerves, today announced the closing of its previously announced underwritten public offering of 4,728,000 shares of its common stock at a price to the public of $2.75 per share resulting in gross proceeds to AxoGen from the offering of approximately $13.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by AxoGen. In addition, the Company announced that the underwriter fully exercised its over-allotment option for the purchase of an additional 709,200 shares, which will result in additional gross proceeds of approximately $2.0 million. The closing of the over-allotment option is expected to be completed on or about February 13, 2015, subject to customary closing conditions. Wedbush PacGrow Life Sciences has acted as sole manager for the offering.
AXGN: 3.45 (+0.02)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 11:45AM CST
IMMU: 3.84 (unch), AXGN: 3.45 (+0.02), CLW: 63.20 (-0.74), QKLS: 2.10 (-0.24), EOPN: 8.55 (-0.01), HSNI: 67.32 (+1.52), LQDT: 9.52 (+0.09), EOX: 1.15 (unch), GLUU: 5.12 (+0.14), WSTL: 1.45 (+0.10), LFVN: 1.11 (-0.02), HSP: 87.35 (unch), GENE: 8.04 (+1.90), ADEP: 6.93 (-0.30), EARS: 5.88 (-0.01), IVC: 17.13 (+0.15), QUIK: 2.17 (+0.01), ENRJ: 2.81 (+0.06), FARM: 24.00 (-0.19), OSUR: 8.13 (+0.06)
AxoGen, Inc. Prices Public Offering of Common Stock
GlobeNewswire - Thu Feb 05, 10:00AM CST
via PRWEB - AxoGen, Inc. (Nasdaq:AXGN), a leading medical technology company with a unique and innovative portfolio of products used to repair injured peripheral nerves, has announced the pricing of an underwritten public offering of 4,728,000 shares of its common stock, offered at a price to the public of $2.75 per share. The gross proceeds to AxoGen from this offering are expected to be approximately $13.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by AxoGen. AxoGen has granted the underwriter an option to purchase up to an additional 709,200 shares during the next 30 days. The offering is expected to close on or about February 10, 2015, subject to customary closing conditions. Wedbush PacGrow Life Sciences is acting as sole manager for the offering.
AXGN: 3.45 (+0.02)
AxoGen, Inc. Announces Proposed Public Offering of Common Stock
GlobeNewswire - Wed Feb 04, 3:29PM CST
via PRWEB - AxoGen, Inc. (Nasdaq:AXGN), a leading medical technology company with a unique and innovative portfolio of products used to repair injured peripheral nerves, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Wedbush PacGrow Life Sciences is acting as sole manager for the offering.
AXGN: 3.45 (+0.02)
AxoGen, Inc. Announces Preliminary Fourth Quarter and Full Year Revenue
GlobeNewswire - Wed Feb 04, 3:17PM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company with a unique and innovative portfolio of products used to repair injured peripheral nerves, today announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2014.
AXGN: 3.45 (+0.02)
AxoGen, Inc. to Host Surgeon Education Event at AAHS ASPN ASRM Joint 2015 Annual Meeting
GlobeNewswire - Thu Jan 22, 6:09AM CST
via PRWEB - AxoGen, Inc. (Nasdaq:AXGN), a leading medical technology company focused on the peripheral nerve repair market, announced that it will sponsor an educational forum for surgeons at the Joint Annual Meetings of the American Association for Hand Surgery, American Society for Peripheral Nerve and American Society for Reconstructive Microsurgery, taking place January 21-27 in Paradise Island, Bahamas.
AXGN: 3.45 (+0.02)
AxoGen, Inc. CMO Jill Schiaparelli and Oral Maxillofacial Surgeon Dr. Shahrokh Bagheri to Discuss Nerve Injury and Repair Options Live on iHeart Business Talk Radio HealthTech Talk Live -- January 10, 2015
Marketwired - Fri Jan 09, 6:15AM CST
AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company dedicated to peripheral nerve repair, announced today that Chief Marketing Officer Jill Schiaparelli will be interviewed live on iHeart Radio's debut episode of HealthTech Talk Live hosted by Ben Chodor and broadcast nationwide on iHeart Radio/ Clear Channel Atlanta Studios - 640 WGST AM this Saturday at 3:00 pm ET. In this exclusive double-segment interview, Ms. Schiaparelli will discuss AxoGen's portfolio of peripheral nerve repair solutions that offers alternatives to patients who require surgical repair of injured peripheral nerves. She will be joined by oral and maxillofacial surgeon and trigeminal nerve repair expert Dr. Shahrokh Bagheri, Chair of Oral and Maxillofacial Surgery at Northside Hospital in Atlanta, to talk about the impact of oral nerve injuries on patients.
AXGN: 3.45 (+0.02)
AxoGen, Inc. CMO Jill Schiaparelli and Oral Maxillofacial Surgeon Dr. Shahrokh Bagheri to Discuss Nerve Injury & Repair Options Live on iHeart Radio HealthTech Talk Live
GlobeNewswire - Fri Jan 09, 6:03AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company dedicated to peripheral nerve repair, announced today that Chief Marketing Officer Jill Schiaparelli will be interviewed live on iHeart Radio's debut episode of HealthTech Talk Live, hosted by Ben Chodor, and broadcasted nationwide on iHeart Radio / Clear Channel Atlanta Studios - 640 WGST AM, this Saturday at 3:00 pm ET. In this exclusive double-segment interview, Ms. Schiaparelli will discuss AxoGen's portfolio of peripheral nerve repair solutions that offers alternatives to patients who require surgical repair of injured peripheral nerves. She will be joined by oral and maxillofacial surgeon and trigeminal nerve repair expert Dr. Shahrokh Bagheri, Chair of Oral and Maxillofacial Surgery at Northside Hospital in Atlanta, about the impact of oral nerve injuries on patients.
AXGN: 3.45 (+0.02)
AxoGen, Inc. Promotes Jill Schiaparelli to Chief Marketing Officer
GlobeNewswire - Tue Jan 06, 6:02AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a growing medical technology company with a unique and innovative portfolio of products used to repair injured peripheral nerves, announced that Jill Schiaparelli has been promoted to the role of Chief Marketing Officer and will focus on the strategy to develop current and expansion nerve repair markets as well as brand and corporate marketing.
AXGN: 3.45 (+0.02)
Will AxoGen (AXGN) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 7:13AM CST
Will AxoGen (AXGN) Continue to Surge Higher?
AXGN: 3.45 (+0.02)
Zacks Rank #1 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
BRLI: 34.63 (+0.06), AXGN: 3.45 (+0.02), AZPN: 38.40 (+0.79), ARQL: 1.35 (+0.04), ADUS: 21.57 (+0.18)
AxoGen, Inc. Avance(R) Nerve Graft Recipient to be honored on Donate Life Rose Parade Float on New Year's Day
GlobeNewswire - Tue Dec 23, 6:02AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a high-growth medical technology company with a unique and innovative portfolio of products used to repair injured peripheral nerves, announced that Shirley Pincus, one of the thousands of patients who have had injured nerves repaired with AxoGen's Avance(R) Nerve Graft, will be honored as a recipient of donated nerve tissue as a float rider in the 2015 Rose Parade aboard the Donate Life Rose Parade Float in Pasadena, California on New Year's Day.
AXGN: 3.45 (+0.02)
AxoGen, Inc. (AXGN) Jumps 5.45% on Insider Buying - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 8:18AM CST
AxoGen, Inc. (AXGN) was a big mover last session, as the company saw its shares rise by over 5% on the day.
AXGN: 3.45 (+0.02), AKRX: 47.28 (-0.25)
PDS Biotechnology, Inc. Announces Appointment of Biotech Industry Leader Sir Richard Sykes to its Board of Directors as Executive Chairman
PR Newswire Europe - Thu Dec 18, 9:41AM CST
PDS Biotechnology, a clinical stage immunotherapeutics company developing the powerful Versamune(R) nanoparticle technology, is delighted to announce that Sir Richard Sykes has accepted an invitation to join the company's board of directors as Executive Chairman.
AXGN: 3.45 (+0.02)
AxoGen perks up
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 8:22AM CST
AXGN: 3.45 (+0.02)
Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
BGFV: 12.53 (+0.17), AXGN: 3.45 (+0.02), BRK.B: 148.34 (-1.45), Y: 475.43 (-0.18), BIOD: 1.38 (-0.14)
AxoGen, Inc. CEO Karen Zaderej to Be Interviewed on Clear Channel - iHeart Business Talk Radio's "The Trader's Network" on December 2
GlobeNewswire - Tue Dec 02, 6:17AM CST
via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a high-growth medical technology company focused on the peripheral nerve repair market, announced today that Chief Executive Officer (CEO) Karen Zaderej will be interviewed live by host Michael Yorba on Clear Channel - iHeart Business Talk Radio's "The Trader's Network" Show. In this exclusive interview, Ms. Zaderej will discuss AxoGen's unique and innovative portfolio of peripheral nerve repair solutions that offer alternatives to the more than 900,000 patients each year who require surgical repair of an injured peripheral nerve. She will also discuss the Company's strong year-on-year growth and its strategy for becoming the market leader of the $1.6 billion peripheral nerve repair market in the US.
AXGN: 3.45 (+0.02)
